Related references
Note: Only part of the references are listed.Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy
Masatoshi Kudo
LIVER CANCER (2012)
Chemoembolization in Patients with Hepatocellular Carcinoma
Riccardo Lencioni
LIVER CANCER (2012)
Epidemiology and Surveillance of Hepatocellular Carcinoma
Do Young Kim et al.
LIVER CANCER (2012)
Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
Masatoshi Kudo
DIGESTIVE DISEASES (2011)
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
Masatoshi Kudo et al.
DIGESTIVE DISEASES (2011)
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)
Masatoshi Kudo et al.
HEPATOLOGY RESEARCH (2010)
Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice
Masatoshi Kudo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
Masatoshi Kudo et al.
ONCOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
